Laboratorios Farmaceuticos Rovi Past Earnings Performance

Past criteria checks 3/6

Laboratorios Farmaceuticos Rovi has been growing earnings at an average annual rate of 21.5%, while the Pharmaceuticals industry saw earnings growing at 13.7% annually. Revenues have been growing at an average rate of 15.7% per year. Laboratorios Farmaceuticos Rovi's return on equity is 23.5%, and it has net margins of 17.9%.

Key information

21.5%

Earnings growth rate

21.7%

EPS growth rate

Pharmaceuticals Industry Growth	12.4%
Revenue growth rate	15.7%
Return on equity	23.5%
Net Margin	17.9%
Last Earnings Update	31 Dec 2024

Recent past performance updates

No updates

Recent updates

No updates

Revenue & Expenses Breakdown

How Laboratorios Farmaceuticos Rovi makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BIT:1ROVI Revenue, expenses and earnings (EUR Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
31 Dec 24	764	137	158	0
30 Sep 24	799	165	155	0
30 Jun 24	778	148	153	0
31 Mar 24	779	138	150	0
31 Dec 23	830	170	147	0
30 Sep 23	837	197	143	0
30 Jun 23	818	186	138	0
31 Mar 23	814	194	134	0
31 Dec 22	818	200	130	0
30 Sep 22	761	176	115	0
30 Jun 22	739	183	110	0
31 Mar 22	724	182	108	0
31 Dec 21	649	153	103	0
30 Sep 21	581	113	95	0
30 Jun 21	519	82	94	0
31 Mar 21	450	71	86	0
31 Dec 20	420	61	85	0
30 Sep 20	413	55	93	0
30 Jun 20	395	53	91	0
31 Mar 20	400	46	93	0
31 Dec 19	381	39	92	0
30 Sep 19	355	33	93	0
30 Jun 19	334	27	93	0
31 Mar 19	310	18	91	0
31 Dec 18	303	18	91	0
30 Sep 18	291	16	90	0
30 Jun 18	283	9	88	0
31 Mar 18	284	18	87	0
31 Dec 17	276	17	85	0
30 Sep 17	277	22	81	0
30 Jun 17	275	24	81	0
31 Mar 17	272	23	80	0
31 Dec 16	265	26	80	0
30 Sep 16	260	25	84	0
30 Jun 16	254	24	84	0
31 Mar 16	246	23	85	0
31 Dec 15	246	20	84	0
30 Sep 15	242	21	53	-9
30 Jun 15	243	23	78	0
31 Mar 15	241	25	76	0
31 Dec 14	238	24	75	0
30 Sep 14	230	24	77	1
30 Jun 14	224	24	77	0
31 Mar 14	221	24	78	0

Quality Earnings: 1ROVI has high quality earnings.

Growing Profit Margin: 1ROVI's current net profit margins (17.9%) are lower than last year (20.5%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 1ROVI's earnings have grown significantly by 21.5% per year over the past 5 years.

Accelerating Growth: 1ROVI's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 1ROVI had negative earnings growth (-19.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (20.9%).

Return on Equity

High ROE: 1ROVI's Return on Equity (23.5%) is considered high.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/03/12 18:24
End of Day Share Price	2025/03/12 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Laboratorios Farmaceuticos Rovi, S.A. is covered by 18 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Álvaro Arístegui Echevarría	Ahorro Corporación
Guilherme Sampaio	Banco BPI, S.A.
Luis Arredondo	Banco de Sabadell. S.A.